Biotech Values

[NP1986]

The selumetinib melanoma data are expected fairly soon, aren't they?

I've been in and out of this stock a few times over the past nine months or so - it's always been quite volatile. It's hard to arrive at a fair valuation of ARRY given that there are still quite a few unknowns with all their assets, but you would hope that at least one of them will end up becoming a commercially viable product. It's still early days, but I think as they start moving molecules into phase III trials the street will start paying more attention. KRAS mutant lung cancer is a huge opportunity for them, especially since they are behind GSK in melanoma.